Stock Research for attbf

attbf

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

attbf Stock Chart & Research Data

The attbf chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the attbf chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


attbf Due diligence Resources & Stock Charts

The attbf stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View attbf Detailed Price Forecast - CNN Money CNN View attbf Detailed Summary - Google Finance
Yahoo View attbf Detailed Summary - Yahoo! Finance Zacks View attbf Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View attbf Trends & Analysis - Trade-Ideas Barrons View attbf Major Holders - Barrons
NASDAQ View attbf Call Transcripts - NASDAQ Seeking View attbf Breaking News & Analysis - Seeking Alpha
Spotlight View attbf Annual Report - CompanySpotlight.com OTC Report View attbf OTC Short Report - OTCShortReport.com
TradeKing View attbf Fundamentals - TradeKing Charts View attbf SEC Filings - Bar Chart
WSJ View Historical Prices for attbf - The WSJ Morningstar View Performance/Total Return for attbf - Morningstar
MarketWatch View the Analyst Estimates for attbf - MarketWatch CNBC View the Earnings History for attbf - CNBC
StockMarketWatch View the attbf Earnings - StockMarketWatch MacroAxis View attbf Buy or Sell Recommendations - MacroAxis
Bullish View the attbf Bullish Patterns - American Bulls Short Pains View attbf Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View attbf Stock Mentions - StockTwits PennyStocks View attbf Stock Mentions - PennyStockTweets
Twitter View attbf Stock Mentions - Twitter Invest Hub View attbf Investment Forum News - Investor Hub
Yahoo View attbf Stock Mentions - Yahoo! Message Board Seeking Alpha View attbf Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for attbf - SECform4.com Insider Cow View Insider Transactions for attbf - Insider Cow
CNBC View attbf Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for attbf - OTC Markets
Yahoo View Insider Transactions for attbf - Yahoo! Finance NASDAQ View Institutional Holdings for attbf - NASDAQ


Stock Charts

FinViz View attbf Stock Insight & Charts - FinViz.com StockCharts View attbf Investment Charts - StockCharts.com
BarChart View attbf Stock Overview & Charts - BarChart Trading View View attbf User Generated Charts - Trading View




Latest Financial News for attbf


Abattis Removed From BCSC Temporary Order
Posted on Thursday January 17, 2019

Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce that the temporary order from the British Columbia Securities Commission (“BCSC”), issued on November 26, 2018 (the “Order”), has not been extended against Abattis. “Abattis is very happy with the BCSC’s decision to remove the Company from the Order such that Abattis can continue to focus its efforts on revenue generation and building shareholder value” stated Rob Abenante, President and CEO of Abattis.


Abattis Enters Into Definitive Share Exchange Agreement With NutriVida
Posted on Thursday January 10, 2019

Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce that, further to its new release dated December 7, 2018, the Company has entered into a definitive share exchange agreement (the “Agreement”) with 1157016 B.C. Ltd., dba NutriVida, a private arm’s length company incorporated in the Province of British Columbia (“NutriVida”), pursuant to which the Company will acquire 100% of the issued and outstanding common shares of NutriVida (the “Acquisition”). In consideration for the Acquisition, and on closing thereof, the Company will issue an aggregate of 58,823,529 common shares (each, a “Share”) in the capital of Abattis, pro rata, to the NutriVida shareholders at a deemed price of $0.085 per Share and make a cash payment of $250,000 as provided in the Agreement.


Abattis Provides Marketing and Operational Updates
Posted on Friday December 21, 2018

Abattis Bioceuticals Corp (the “Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to announce the launch of its new website and provide an operational update. Abattis has recently unveiled its new marketing and branding materials, developed in conjunction with media company Canada One Communications Inc. (“Canada One”). Marketing materials include an updated website, corporate presentation and conference materials all highlighting Abattis’ new brand imagery (“new marketing materials”).


Vergence Naturals and Naturopathic Doctor and Nutraceutical Product Developer Brazos Minshew Launch Comfort
Posted on Tuesday December 18, 2018

VANCOUVER, British Columbia, Dec. 18, 2018 /PRNewswire/ -- Abattis Bioceuticals Corp (the "Company" or "Abattis") (ATT.CN) (ATTBF) is pleased to announce its first proprietary product, Comfort,  which has been produced through wholly owned subsidiary Vergence Naturals ("Vergence"). Abattis has teamed up with respected naturopathic doctor and nutraceuticals product developer Dr. Brazos Minshew to launch Comfort, a breakthrough nutraceutical combining traditional herbal remedies to safely and effectively address occasional pain. Released on Cyber Monday and set for introduction into the US and Canada in December 2018, the Comfort product is 100% owned by Vergence, and will be marketed under the newly-formed health and wellness brand.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.